Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

• Armando Santoro,
• Garrido Pilar,
• Daniel S.W. Tan,
• Jon Zugazagoitia,
• Frances A. Shepherd,
• Alessandra Bearz,
• Fabrice Barlesi,
• Tae Min Kim,
• Tobias R. Overbeck,
• Enriqueta Felip,
• Can Cai,
• Simantini Eddy,
• Tracey McCulloch,
• Eric S. Schaefer

Affiliations

Armando Santoro

Department of Biomedical Sciences, Humanitas University

Garrido Pilar

Department of Medical Oncology, Hospital Ramón Y Cajal

Daniel S.W. Tan

Department of Medical Oncology, National Cancer Center Singapore

Jon Zugazagoitia

Department of Medical Oncology, University Hospital

Frances A. Shepherd

Department of Medical Oncology and Hematology

Alessandra Bearz

Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO

Fabrice Barlesi

Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP

Tae Min Kim

Department of Internal Medicine, Seoul National University Hospital

Tobias R. Overbeck

Department of Hematology and Medical Oncology, University Medical Center Göttingen

Enriqueta Felip

Department of Medical Oncology Service, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology

Can Cai

Novartis Pharmaceuticals Corporation

Simantini Eddy

Novartis Pharmaceuticals Corporation

Tracey McCulloch

Novartis Pharma AG

Eric S. Schaefer

Department of Medical Oncology, Highlands Oncology Group